Objective Entecavir(ETV) was superior to lamivudine(LMV) in achieving histologic improvement,ALT normalization and HBV DNA suppression at week 48 in phase III trials.

• 目的III期临床研究结果显示恩替卡韦(ETV)治疗48周,在组织学改善、ALT复常和HBVDNA抑制方面均优于拉米夫定(LMV);